Prevalence of polypharmacy use and association with mortality: a cohort study of elderly people in Southern Brazil, 2014-2017.

IF 2.5 Q1 Multidisciplinary

Epidemiologia e Servicos de Saude Pub Date : 2025-04-07 eCollection Date: 2025-01-01 DOI:10.1590/S2237-96222025v33e20240081.en

Cristina Heloisa Müller, Andréa Dâmaso Bertoldi, Renata Moraes Bielemann, Karla Pereira Machado, Elaine Tomasi, Maria Cristina Gonzalez, Marysabel Pinto Telis Silveira

{"title":"Prevalence of polypharmacy use and association with mortality: a cohort study of elderly people in Southern Brazil, 2014-2017.","authors":"Cristina Heloisa Müller, Andréa Dâmaso Bertoldi, Renata Moraes Bielemann, Karla Pereira Machado, Elaine Tomasi, Maria Cristina Gonzalez, Marysabel Pinto Telis Silveira","doi":"10.1590/S2237-96222025v33e20240081.en","DOIUrl":null,"url":null,"abstract":"Objective: To characterize prevalence of polypharmacy use and its association with mortality in elderly people.Methods: Prospective cohort (2014 to 2017), with non-institutionalized individuals aged 60 years or over, living in Pelotas, Rio Grande do Sul, Brazil. Association between polypharmacy and mortality was analyzed using Cox regression. Hazard ratios (HR) and their respective 95% confidence intervals (95%CI) were calculated, following the Cox proportional hazards model. Interaction between age groupand multimorbidity was considered to be statistically significant when p-value<0.100.Results: Results: Polypharmacy prevalence was 36.1% (95%CI 33.7; 38.6), being higher as age group increased (29.8% in those aged 60-69; 41.3% in those aged 70-79). and 47.8% inthose aged 80 years and over). In the adjusted analysis, risk of mortality was 62% higher among elderly people using polypharmacy (HR 1.62; 95%CI 1.10; 2.39), without interaction between age group (p-value 0.750) and multimorbidity (p-value 0.312). Thesurvival analysis demonstrated that the probability of survival was lower in elderly people using polypharmacy (85.6%).Conclusion: Polypharmacy prevalence was found to be higher as age group increased and elderly people using polypharmacy had higher risk of mortality, regardless of age group and presence of multimorbidity.","PeriodicalId":51473,"journal":{"name":"Epidemiologia e Servicos de Saude","volume":"34 ","pages":"e20240081"},"PeriodicalIF":2.5000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiologia e Servicos de Saude","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/S2237-96222025v33e20240081.en","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Multidisciplinary","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To characterize prevalence of polypharmacy use and its association with mortality in elderly people.

Methods: Prospective cohort (2014 to 2017), with non-institutionalized individuals aged 60 years or over, living in Pelotas, Rio Grande do Sul, Brazil. Association between polypharmacy and mortality was analyzed using Cox regression. Hazard ratios (HR) and their respective 95% confidence intervals (95%CI) were calculated, following the Cox proportional hazards model. Interaction between age groupand multimorbidity was considered to be statistically significant when p-value<0.100.

Results: Results: Polypharmacy prevalence was 36.1% (95%CI 33.7; 38.6), being higher as age group increased (29.8% in those aged 60-69; 41.3% in those aged 70-79). and 47.8% inthose aged 80 years and over). In the adjusted analysis, risk of mortality was 62% higher among elderly people using polypharmacy (HR 1.62; 95%CI 1.10; 2.39), without interaction between age group (p-value 0.750) and multimorbidity (p-value 0.312). Thesurvival analysis demonstrated that the probability of survival was lower in elderly people using polypharmacy (85.6%).

Conclusion: Polypharmacy prevalence was found to be higher as age group increased and elderly people using polypharmacy had higher risk of mortality, regardless of age group and presence of multimorbidity.

查看原文本刊更多论文

2014-2017年巴西南部老年人使用多种药物的患病率及其与死亡率的关系

目的：了解老年人使用多种药物的流行情况及其与死亡率的关系。方法：前瞻性队列（2014年至2017年），年龄在60岁或以上的非机构个体，居住在巴西南巴西大德州佩洛塔斯。采用Cox回归分析多药与死亡率的关系。根据Cox比例风险模型计算风险比（HR）和各自的95%置信区间（95% ci）。当p值为0.100时，认为年龄组与多病之间的相互作用具有统计学意义。结果：多药使用率为36.1% (95%CI为33.7；38.6%)，随着年龄的增加而增加(60-69岁为29.8%；70-79岁占41.3%)。80岁及以上的占47.8%)。在调整后的分析中，使用多种药物的老年人死亡风险高出62% (HR 1.62；95%可信区间1.10;2.39)，年龄组与多发病无交互作用（p值0.750）（p值0.312）。生存分析表明，老年人多药联用的生存率较低（85.6%）。结论：随着年龄的增加，使用多种药物的老年人死亡率更高，与年龄和是否存在多种疾病无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊